Streetbeat News

Products Services

CTVA

EVGN

Evogene's subsidiary, Lavie Bio, has announced a licensing agreement for bio-fungicides with Corteva Agriscience. The agreement grants Corteva the rights to further develop and commercialize bio-fungicide product candidates.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:33 am

BIVI

Biovie has announced data from a Phase 2 exploratory biomarker study, detailing the epigenetic basis for how its NE3107 may have potentially regulated specific genes. This regulation is significantly correlated with observed cognitive and biomarker improvements.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:16 am

VIRI

Virios Therapeutics has announced data showing improvement in multiple long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib. The data comes from an exploratory, open-label, proof of concept study.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:10 am

CLSD

Clearside Biomedical has announced the enrollment of multiple participants in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in Wet AMD.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:10 am

ATHA

Athira Pharma has presented new preclinical data at the Alzheimer's Association International Conference in Amsterdam, demonstrating the neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity. Additionally, ATH-1105 has shown protection against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:09 am

CGEN

Compugen Ltd. has announced that the European Patent Office has successfully maintained broad claims of its anti-PVRIG antibodies for use in treating cancer patients.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:08 am

IVVD

Invivyd has announced additional initial data from its ongoing Phase 1 clinical trial of monoclonal antibody candidate, VYD222, for the prevention of symptomatic Covid-19 in immunocompromised people.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:08 am

GKOS

Glaukos Corporation (GKOS) has announced that it will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR system.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:07 am

TNXP

Tonix Pharmaceuticals has announced an agreement and the initiation of enrollment in a Phase 2 trial with the University of Washington. The trial will study TNX-1900, a potentiated intranasal oxytocin, for the treatment of social anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:06 am

BLRX

BioLineRx has initiated a Phase 2 trial for first-line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. The trial includes the investigational candidate Motixafortide.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:05 am